Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
glycoprotein E + CpG 1018 + alum
- Development stage
- Unknown
- Lead developer
- Dynavax Technologies
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A combination vaccine formulation consisting of **glycoprotein E** (gE) antigen, **CpG 1018** (a synthetic Toll-like receptor 9 [TLR9] agonist oligonucleotide adjuvant), and **alum** (aluminum hydroxide adjuvant). This combination is under development notably as a recombinant subunit vaccine against **herpes zoster (shingles)**, and studied in other vaccine candidates. **gE** serves as the immunogen; **CpG 1018** functions as an immunostimulatory adjuvant to promote a Th1-biased immune response; and **alum** further enhances immunogenicity. The combination has demonstrated dose-sparing effects and robust induction of antibody and cellular immunity[1][2][4][5]. CpG 1018 is also FDA-approved as an adjuvant in the hepatitis B vaccine HEPLISAV-B but is used here in combination with alum for potentially greater immunogenicity in other vaccine platforms[1][3][5].
- Other names
- gE + CpG 1018 + alum
02
Targets
gE (VZV glycoprotein E)TLR9 (Toll-like receptor 9)
Beyond the preview
Go deeper on glycoprotein E + CpG 1018 + alum.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on glycoprotein E + CpG 1018 + alum.